Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2015 4
2016 1
2017 1
2018 1
2020 1
2021 1
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I-Indole Derivatives.
Stypik M, Zagozda M, Michałek S, Dymek B, Zdżalik-Bielecka D, Dziachan M, Orłowska N, Gunerka P, Turowski P, Hucz-Kalitowska J, Stańczak A, Stańczak P, Mulewski K, Smuga D, Stefaniak F, Gurba-Bryśkiewicz L, Leniak A, Ochal Z, Mach M, Dzwonek K, Lamparska-Przybysz M, Dubiel K, Wieczorek M. Stypik M, et al. Among authors: gunerka p. Pharmaceuticals (Basel). 2022 Jul 30;15(8):949. doi: 10.3390/ph15080949. Pharmaceuticals (Basel). 2022. PMID: 36015098 Free PMC article.
Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II-Benzimidazole Derivatives.
Stypik M, Michałek S, Orłowska N, Zagozda M, Dziachan M, Banach M, Turowski P, Gunerka P, Zdżalik-Bielecka D, Stańczak A, Kędzierska U, Mulewski K, Smuga D, Maruszak W, Gurba-Bryśkiewicz L, Leniak A, Pietruś W, Ochal Z, Mach M, Zygmunt B, Pieczykolan J, Dubiel K, Wieczorek M. Stypik M, et al. Among authors: gunerka p. Pharmaceuticals (Basel). 2022 Jul 27;15(8):927. doi: 10.3390/ph15080927. Pharmaceuticals (Basel). 2022. PMID: 36015075 Free PMC article.
Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma.
Gunerka P, Gala K, Banach M, Dominowski J, Hucz-Kalitowska J, Mulewski K, Hajnal A, Mikus EG, Smuga D, Zagozda M, Dubiel K, Pieczykolan J, Zygmunt BM, Wieczorek M. Gunerka P, et al. PLoS One. 2020 Jul 23;15(7):e0236159. doi: 10.1371/journal.pone.0236159. eCollection 2020. PLoS One. 2020. PMID: 32702053 Free PMC article.
A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus.
Dulak-Lis M, Bujak A, Gala K, Banach M, Kędzierska U, Miszkiel J, Hucz-Kalitowska J, Mroczkiewicz M, Stypik B, Szymczak K, Gunerka P, Dubiel K, Zygmunt BM, Wieczorek M, Pieczykolan JS. Dulak-Lis M, et al. Among authors: gunerka p. J Pharmacol Sci. 2021 Apr;145(4):340-348. doi: 10.1016/j.jphs.2021.02.002. Epub 2021 Feb 9. J Pharmacol Sci. 2021. PMID: 33712286 Free article.
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
Zdzalik D, Dymek B, Grygielewicz P, Gunerka P, Bujak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K. Zdzalik D, et al. Among authors: gunerka p. J Cancer Res Clin Oncol. 2014 Apr;140(4):589-98. doi: 10.1007/s00432-014-1589-3. Epub 2014 Feb 8. J Cancer Res Clin Oncol. 2014. PMID: 24509625 Free PMC article.
11 results